OncoTherapy Hit By Dropped Alliances
This article was originally published in PharmAsia News
Executive Summary
The Japanese bioventure OncoTherapy Science (OTS) has been hit by the discontinuation of alliances with two compatriot firms for some of its key pipeline cancer projects.